Devices, systems and methods are described that can facilitate recognition of an engagement between an object and a touch screen in the absence of human contact. Upon the engagement, an electrically conductive path can be established that extends from a surface of the touch screen such that sufficient electrons flow from the touch screen through the electrically conductive path to enable the recognition of the object on the touch screen in the absence of human contact with the object during continued presence of the object on the touch screen.

Therapy delivery to a patient may be controlled based on a determined sleep stage of the patient. In examples, the sleep stage may be determined based on a frequency characteristic of a biosignal indicative of brain activity of the patient. A frequency characteristic may include, for example, a power level within one or more frequency bands of the biosignal, a ratio of the power level in two or more frequency bands, or a pattern in the power level of one or more frequency bands over time. A therapy program may be selected or modified based on the sleep stage determination. Therapy may be delivered during the sleep stage according to the selected or modified therapy program. In some examples, therapy delivery may be controlled after making separate determinations of a sleep stage based on the biosignal and another physiological parameter, and confirming that the sleep stage determinations are consistent.

A drug infusion system located at least partially external to the patient having a pump and an external patient programmer control configured to allow adjustment of therapy. Adjustment may include setting, selecting and adjusting the transition period between drug delivery rates. The system can present to the patient an alert related to the adjustment and receive patient input information in response thereto. A patient response rule module is configured to apply a rule to the input information provided by a patient. For example, the patient response rule can be used to provide an insulin pump setting according to the patient response rule or to provide a setting, or to provide a setting that is proposed to the user. Other systems and methods are also described such as asking questions related to the adjustment of future therapy settings.

Methods are provided for non-invasive early screening of a subject for a neurodegenerative disorder, by analyzing one or more parameters associated with the neurodegenerative disorder.

A method and system for predicting neurological disorders is provided. The method comprises receiving videos of individuals and detecting Regions of Interest (ROI) in video frames. The method further comprises determining a Motion Vector (MV) for each ROI in a set of successive frames and comparing value of the determined MV with pre-stored values. Furthermore, the method comprises identifying a MV matching a pre-stored value thereby identifying a ROI and a frame corresponding to the identified MV, wherein the pre-stored value indicates onset of an expression. Also, the method comprises determining MVs for the identified ROI in subsequent sets of successive frames and comparing value of the determined MVs with a pre-stored value of MV corresponding to peak and offset of the indicated expression. The method further comprises identifying the frame corresponding to the peak and offset of the indicated expression and generating pictorial representation for predicting neurological disorders.

Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for treatment of coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia. Described are methods and devices to treat coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia that involves no medication. Methods and devices described herein use alternating magnetic fields to gently tune the brain and affect symptoms of coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia.

Therapy delivery to a patient may be controlled based on a determined sleep stage of the patient. In examples, the sleep stage may be determined based on a frequency characteristic of a biosignal indicative of brain activity of the patient. A frequency characteristic may include, for example, a power level within one or more frequency bands of the biosignal, a ratio of the power level in two or more frequency bands, or a pattern in the power level of one or more frequency bands over time. A therapy program may be selected or modified based on the sleep stage determination. Therapy may be delivered during the sleep stage according to the selected or modified therapy program. In some examples, therapy delivery may be controlled after making separate determinations of a sleep stage based on the biosignal and another physiological parameter, and confirming that the sleep stage determinations are consistent.

A method, system, and computer-readable medium receive module configuration settings to configure a customized human movement examination module for a human movement examination item. A patient is instructed with audio instructions associated with the customized human movement examination module. A single camera is controlled having progressive scan capabilities according to the module configuration settings to allow recording of a performance by the patient of the human movement examination item. The recorded data is analyzed based on the information provided by the single camera to measure human movement exhibited by the patient.

The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not limited to, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention also provides methods of differentiating white matter from gray matter. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using sensors. The invention further provides methods of measuring the neurotoxicity of a material by comparing microvoltammograms of a neural tissue in the presence and absence of the material using the inventive sensors.

A system and method for measuring and analyzing locomotion is provided. The system may include a gait analysis apparatus that is configured to provide multi-dimensional measurements of the gait of an individual as the individual traverses the apparatus. The multiple dimensions may include force, space, time, and frequency. The gait analysis apparatus may be configured to provide a gait measurement processing device with the multi-dimensional measurements. Based on the multi-dimensional measurements, the gait measurement processing device may, for example, diagnose the test subject with a particular NM disease and/or injury, monitor progression of the particular NM disease and/or injury over time, and determine which measurements may be used as biomarkers to identify the particular NM disease and/or injury.